Cambridge Heart Appoints New Vice President; Mark S. Florence Hired to Lead Sales and Marketing Effort.

BEDFORD, Mass. -- Cambridge Heart, Inc. (OTCBB-CAMH) today announced that it has hired Mr. Mark Florence as its Vice President, Sales and Marketing. Mr. Florence has extensive experience over the last 20 years in the cardiac medical device and diagnostic industry. He has held positions of increasing responsibility in marketing, sales and general management with industry leaders such as Abbott Laboratories, Bayer and the Moore Medical Subsidiary of McKesson.

Most recently Mr. Florence was Vice President of Sales at CardioDynamics where he was responsible for growing the sales force from 3 to 5 regions totaling 60 direct sales representatives. Additionally, Mr. Florence had matrix management responsibility for the company's nurse clinical applications team, during which time the team grew from 15 to 25 members.

Mr. Florence holds a BS Degree in Marketing from Northeastern University and an MBA from the Northeastern University Graduate School of Business in Boston.

Commenting on this new addition to the executive management team, David Chazanovitz, President and CEO of Cambridge Heart said the following. "Mark is an excellent, high level addition to Cambridge Heart. He is uniquely qualified to lead our sales and marketing team to the next level. His experience in growing a direct sales team, supported by clinical applications specialists is exactly what we need to drive future revenue. Having been intimately involved in selling capital equipment and disposables to the office based cardiologist, we are extremely fortunate to now have his knowledge and experience resident at Cambridge Heart. While I am very pleased with our sales momentum and gains in reimbursement, Mark will lead the charge to achieving our revenue expectations during the next phase of our growth."

Mr. Robert LaRoche, former Vice President, Sales and Marketing has left the company to pursue other interests.

About Cambridge Heart

Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, the Company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary technology, Microvolt T-Wave Alternans, and are the first diagnostic tools cleared by the U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave alternans. The Company, founded in 1990, is based in Bedford, Massachusetts and is traded on the OTCBB under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com

About the Cambridge Heart Microvolt T-Wave Alternans Test

The Cambridge Heart Microvolt T-Wave Alternans Test measures extremely subtle beat-to-beat fluctuations in a person's heartbeat called T-wave alternans. These tiny heartbeat variations - measured at one millionth of a volt - are detected in any clinical setting where titration of the heart rate is possible. The preparation for the test consists of placing proprietary sensors on a patient's chest. Extensive clinical research has shown that patients with symptoms of or, who are at risk of, life threatening arrhythmias who test positive for T-wave alternans are at significant risk for subsequent sudden cardiac events including sudden death, while those who test negative are at minimal risk.

Statements contained in this press release about anticipated revenue growth, and all other statements that are not purely historical, are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as "believes", "expects", "anticipates", "plans", "estimates", "could" and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include customer delays in making final buying decisions, decreased demand for our products, failure to obtain funding necessary to develop or enhance our technology, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology, failure to obtain or maintain adequate levels of third-party reimbursement for use of our products and other factors identified in our most recent Annual Report on Form 10-K under "Factors Which May Affect Future Results", which is on file with the SEC. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.